Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial (Q90884647)
Jump to navigation
Jump to search
scientific article published on 01 November 2018
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial |
scientific article published on 01 November 2018 |
Statements
Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial (English)
Baohui Han
Kai Li
Qiming Wang
Li Zhang
Jianhua Shi
Zhehai Wang
Ying Cheng
Jianxing He
Yuankai Shi
Yizhuo Zhao
Hao Yu
Yang Zhao
Weiqiang Chen
Yi Luo
Xiuwen Wang
Robert Pirker
Kejun Nan
Faguang Jin
Jian Dong
Baolan Li